Cystic fibrosis-related diabetes (CFRD) is a distinct form of diabetes that develops in roughly 20 percent of adolescents and up to 50 percent of adults with cystic fibrosis. It results from progressive pancreatic islet damage in the context of chronic exocrine pancreatic disease and is treated with insulin only. Dietary advice deliberately diverges from typical diabetes nutrition — calories and fat are maintained or increased to support weight and lung function.
What Is CFRD?
Cystic fibrosis is a multisystem genetic disease caused by mutations in the CFTR gene, affecting chloride transport across epithelial surfaces. Thick secretions obstruct the airways and pancreatic ducts. Over time, pancreatic exocrine tissue is destroyed by inflammation, fibrosis, and fat infiltration; islet cells in the surrounding tissue are eventually damaged, leading to insulin deficiency.
CFRD is classified as a form of secondary diabetes — type 3c pancreatogenic diabetes — but it has unique features that distinguish it from other forms of pancreatic diabetes, including a specific natural history and management approach codified in international consensus guidelines.
How CFRD Differs from Type 1 and Type 2 Diabetes
| Feature | Type 1 | CFRD | Type 2 |
|---|---|---|---|
| Mechanism | Autoimmune | Pancreatic damage from CF | Insulin resistance plus beta-cell decline |
| Autoantibodies | Positive | Negative | Negative |
| Onset | Childhood to young adult | Usually adolescence or adulthood | Usually middle age |
| Body habitus | Variable, often lean | Lean, often underweight | Often overweight |
| Insulin secretion | Severely reduced | Reduced — particularly first-phase | Normal early, declines |
| Insulin resistance | Not central | Worsens during pulmonary exacerbations | Central feature |
| DKA risk | High | Low | Low |
| Treatment | Insulin | Insulin only | Lifestyle plus orals plus possibly insulin |
| Dietary advice | Carbohydrate counting | High calorie, high fat, no carb restriction | Carbohydrate moderation typical |
Causes and Mechanisms
- Pancreatic fibrosis and fat infiltration damage islets over years
- First-phase insulin secretion is lost early — even before fasting hyperglycemia
- Inflammation from pulmonary exacerbations transiently worsens insulin resistance
- Glucocorticoids used for CF lung disease can further raise glucose
- Enteral feeds and high-calorie diets unmask post-meal hyperglycemia
- Genetic background — homozygous F508del and some other genotypes are associated with higher CFRD risk
Why CFRD Matters Beyond Glucose
Onset of CFRD is associated with declining clinical status that precedes the actual diabetes diagnosis:
- Unexplained weight loss
- Declining FEV1 (lung function)
- More frequent pulmonary exacerbations
- Increased mortality
Insulin therapy in CFRD improves nutritional status, weight, and lung function — making early identification and treatment particularly valuable.
Symptoms
- Often asymptomatic at first — caught on routine OGTT screening
- Unexplained weight loss despite good appetite and food intake
- Decline in pulmonary function
- Increased thirst and urination
- Fatigue
- Slowed growth or delayed puberty in adolescents
- More frequent infections
- Blurred vision
Screening and Diagnosis
Annual OGTT
The Cystic Fibrosis Foundation and ADA recommend an annual oral glucose tolerance test (OGTT) starting at age 10 in everyone with cystic fibrosis. The OGTT is more sensitive than A1C or fasting glucose in this population because:
- A1C is often falsely low in CF (red blood cell turnover, chronic illness)
- Fasting glucose can remain normal long after post-meal glucose has risen
Diagnostic Categories
| Glucose Category | OGTT Result |
|---|---|
| Normal glucose tolerance | 2-hour glucose under 140 mg/dL |
| Indeterminate glycemia (INDET) | Mid-OGTT (30, 60, 90 min) ≥200 mg/dL but 2-hour under 140 |
| Impaired glucose tolerance (IGT) | 2-hour glucose 140 to 199 mg/dL |
| CFRD without fasting hyperglycemia | 2-hour glucose ≥200 mg/dL, fasting under 126 |
| CFRD with fasting hyperglycemia | Fasting glucose ≥126 mg/dL |
Other Diagnostic Considerations
- During pulmonary exacerbations or steroid courses — special diagnostic rules apply because glucose is transiently elevated
- Continuous glucose monitoring is increasingly used for sensitive detection of early dysglycemia
- C-peptide is usually reduced but variable
- Pancreatic autoantibodies — negative (helps distinguish from coincident type 1 diabetes)
Treatment
Insulin Is the Only Approved Therapy
- Basal-bolus insulin or pump therapy — matched to meals and high-fat, high-calorie diet
- Pre-meal rapid-acting insulin dosed by carbohydrate count plus, often, fat-protein adjustments
- Basal insulin to cover overnight and fasting periods
- Frequent dose adjustments during pulmonary exacerbations and glucocorticoid courses
- Continuous glucose monitoring is widely used to support intensive insulin therapy
- Oral diabetes medications are not recommended — insufficient evidence and potential weight loss
Nutrition
- Continue high calorie, high fat diet to maintain weight and lung function
- No carbohydrate restriction — insulin is matched to the diet, not the other way around
- Adequate salt intake — CF patients lose more sodium
- Pancreatic enzyme replacement (PERT) with meals and snacks
- Fat-soluble vitamin supplementation (A, D, E, K)
- Work with a registered dietitian experienced in CF
Coordinated CF Care
- Pulmonary management — airway clearance, mucolytics, CFTR modulators
- Treatment of pulmonary infections — IV antibiotics during exacerbations
- Liver disease screening — CF can affect liver function
- Bone health — osteoporosis is common in CF and worsens with diabetes
- Mental health support — chronic disease burden is high
CFTR Modulators and CFRD
Newer CFTR modulator therapies (elexacaftor-tezacaftor-ivacaftor and earlier agents) have transformed cystic fibrosis care. Their effect on CFRD is still being characterized — some patients show improved insulin secretion and glucose tolerance after starting modulator therapy, but most established CFRD does not reverse. Monitoring continues as before.
Pregnancy and CFRD
- Pregnancy is increasingly common in women with CF
- CFRD increases gestational complications — preterm birth, macrosomia
- Tight glycemic control with insulin is essential before conception and through pregnancy
- Multidisciplinary preconception counseling
Complications
- Decline in lung function and increased pulmonary exacerbations
- Weight loss and undernutrition
- Increased mortality
- Standard diabetes microvascular complications (retinopathy, nephropathy) can occur with longer disease duration — see complications and related conditions
- Bone disease — both CF and diabetes contribute
- Macrovascular disease is less common than in typical type 2 diabetes
Prevention
CFRD cannot be prevented because it is a consequence of the underlying cystic fibrosis. Prevention efforts focus on:
- Early detection through annual OGTT from age 10
- Aggressive treatment of pulmonary exacerbations to limit transient insulin resistance episodes
- Optimal nutrition to support weight
- Early insulin initiation when CFRD is confirmed
- Multidisciplinary CF center care
Related Reading
See our companion guides on type 3c pancreatogenic diabetes, secondary diabetes, diet and nutrition, and the prediabetes basics hub.
The Bottom Line
CFRD is a distinct form of diabetes seen in roughly half of adults with cystic fibrosis. It is neither type 1 nor type 2 — insulin deficiency from pancreatic damage is the underlying mechanism, with insulin resistance worsening during pulmonary exacerbations. Annual OGTT screening from age 10 catches early disease before symptoms develop. Insulin is the only approved treatment, and dietary advice deliberately diverges from typical diabetes nutrition — high calorie, high fat, no carb restriction — to support weight and lung function. Care should be coordinated through a cystic fibrosis center.
